US › Healthcare

Nurix Therapeutics Inc (NRIX)

US · Healthcare · Biotechnology

$24.69+6.33%
Last close · 2026-08-04

Latest quarter · ended 2026-05-31

Revenue
$9.0M
Revenue YoY
-79.5%
Net profit
$-89.5M
Profit YoY
-106.0%
EPS
$-0.81
EPS estimate
$-0.73
Net margin
-990.1%

EPS came in at -0.81 against a street estimate of -0.73 — a miss of 11.0%.

Key statistics

Market cap
$2.41B
Forward P/E
0.0
P/B
5.98
Book value
$3.88
EPS (TTM)
$-3.46
52-week high
$25.09
52-week low
$8.20
50-day MA
$20.39
200-day MA
$17.09
Beta
1.80

Analyst view

Analysts rate Nurix Therapeutics Inc a buy (16 buy, 2 hold, 0 sell out of 18) with an average price target of $33.12.

Shareholding

Insiders
1.08%
Institutions
115.21%

Largest institutional holders

FundStake
BlackRock Inc8.60%
Redmile Group, LLC7.45%
Vestal Point Capital LP6.26%
Deep Track Capital, LP6.11%
Vanguard Group Inc5.73%
FMR Inc5.34%
State Street Corp4.95%
Morgan Stanley - Brokerage Accounts4.75%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nurix Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.